)
Pfizer struggles amid Covid decline
Pfizer's shares take a nosedive after a disappointing forecast for next year, revealing that its ambitious $43 billion takeover of seagen may not be enough to counter the diminishing returns from its covid franchise.
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)